• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Sept. 23, 2025, 2:00 PM EDTBy Max GaoCanadian comic Mae Martin knows their new Netflix limited series — which blends light-hearted comedic elements with the anxiety-inducing horror and thriller genres — may feel like a dramatic departure for anyone who is familiar with their stand-up routines and their semi-autobiographical show, “Feel Good.”“It’s funny because it doesn’t feel like a departure for me,” Martin, who identifies as nonbinary and uses they/them pronouns, told NBC News. “It feels thematically in the same universe as everything I do. It’s introspective, and there’s themes about processing adolescence and identity.”“Wayward,” which premieres Thursday, stars Martin as Alex Dempsey, a police officer who has just moved to the seemingly picturesque small town of Tall Pines with his pregnant wife, Laura (Sarah Gadon). During one of his first days in the city, where his wife grew up, Alex crosses paths with two students from the local academy for “troubled teens” who are desperately trying to plot their escape. As he begins investigating a series of unusual incidents, Alex suspects that Evelyn Wade (Toni Collette) — the school’s enigmatic leader who shares a troubling personal connection with Laura — might be at the center of all the town’s problems.“Alex is sort of the eyes of the audience and trying to piece it all together. It’s so seductive to be in a town that is so accepting and progressive on the surface and is offering him everything he’s always dreamed of,” Martin explained. But over the course of eight episodes, Alex, who is a transgender man, “is grappling with his moral compass and also his intense yearning to have that nuclear family and mainstream acceptance that he’s always wanted.”After Martin rose to fame internationally during the Covid-19 pandemic for co-creating the romantic dramedy series “Feel Good,” in which they played a fictionalized version of themselves, some viewers may have expected the writer to create a new project that would feel similarly autobiographical. But Martin said they have been wanting to make a show for decades set against the backdrop of the “troubled teen industry,” a term used for the broad range of controversial youth residential programs aimed at struggling teenagers.“My best friend Nicole got sent to a troubled teen institute in the States, and she was gone for about two years,” said Martin, who grew up in Toronto. “That sparked my interest in some of the shadier practices and the really strange origins of that industry, which all trace back to self-help cults in the 1970s and this really theatrical behavioral modification.”At first, Martin thought the series would be more of a classic, coming-of-age story in the vein of “Stand By Me” or “Holes.” But after hearing about their best friend’s harrowing experiences at one of those unregulated schools — where she recalled being starved, sleep deprived and forced to dig and stand in her own grave overnight — Martin could tell that a tale about troubled teens being held against their will would be much more in line with classic horror and thriller films such as “Fargo,” “Get Out” and “Rosemary’s Baby.”Over time, Martin said, they became more interested in looking “directly at how many young people are pathologized at such a young age, just for having a pretty normal reaction to a sick society.” “When you take kids who are in crisis and your reaction is punitive, you take away their opportunity to go through all the normal milestones of development, and you ascribe labels to them that really affect how they see their own potential,” they said. Mae Martin and Toni Collette in “Wayward.”Michael Gibson / NetflixMartin said they have found themselves increasingly thinking about “the state of the world that we’re passing down to young people, and about intergenerational conflict.”“As we get older, we suppress so much of our sensitivity and our critical thinking and even our empathy just in order to survive in the world,” Martin said. “So we can’t help but kind of gaslight young people out of their very correct observation that the world is insane, and that there’s a lot of hypocrisy out there.”From the outset, Martin said, they knew they wanted to play Alex. While his gender identity is only explored in passing, “a lot of his inner yearning is connected to that and how he sees himself and wants to be seen in the world,” especially as a husband and an expectant father, Martin explained.“The show’s set in 2003, and I think there wasn’t a lot of fluency around nonbinary identity then and not a lot of they/thems,” Martin noted, adding that playing a man “just made sense” to them. “Who knows where I’ll end up on that spectrum? But it felt pretty natural to me as an actor — more natural than it would’ve been to play a woman.”As the creator and co-showrunner of “Wayward,” Martin is one of the few LGBTQ writers in Hollywood who are shepherding their own mainstream projects. While they said they try not to think too much about their public profile when creating their projects, Martin said it is “scary” to be a queer creative at a time when President Donald Trump and conservatives have been actively targeting and rolling back legal protections for the queer community, especially trans and nonbinary people.Toni Collette and Joshua Close in “Wayward.”Netflix“What makes things difficult is when things are charged politically, like they are now, it makes it seem like even having a trans character or a gay character is a political statement and immediately puts your project in a niche category,” said Martin. “It’s crazy that your career can be affected by political swings like that.”Martin said they see their visibility as a prominent nonbinary comedian in the current climate as a double-edged sword. On the one hand, they want to tell stories that will reach the widest audience possible and, hopefully, in turn, create more empathy for the LGBTQ community. But at the same time, Martin said, they know that their mere existence can be seen as a kind of political statement.They said they would welcome an environment where an LGBTQ character’s identity was “just incidental,” rather than a defining feature of the project, “and the focus is actually on these hugely universal themes and storylines.”In “Wayward,” for instance, “there are nuances that are specific to the queer experience that I think queer people will pick up on and relate to, but those things are pretty relatable to anyone who’s experienced any kind of otherness,” Martin said.Martin speculated that the heightened backlash against the trans community is connected to depictions of trans people that have disproportionately focused on transphobia, bigotry and trauma. “It is a part of the trans experience, but it’s just one small part of a human experience,” they said. “The more we can have diverse characters who are flawed, funny, weird and relatable, who make mistakes, who have relationships — I think that would be more helpful.”Martin acknowledged there’s been a contraction in the output of diverse stories, but they plan to keep “sneaking subversive things” into more mainstream projects.“I’ll just keep my head down, keep inundating people with scripts, and hope to ride it out and do my part,” Martin said.Max GaoMax Gao is a freelance entertainment and sports journalist based in Toronto. He has written for NBC News, The New York Times, the Los Angeles Times, Sports Illustrated, The Daily Beast, Harper’s Bazaar, Elle, Men’s Health, Teen Vogue and W Magazine. 

admin - Latest News - September 23, 2025
admin
30 views 15 secs 0 Comments




The new Netflix horror-comedy “Wayward” stars Mae Martin as a trans cop who has just moved to a seemingly picturesque small town with his pregnant wife.



Source link

TAGS:
PREVIOUS
Students speak out against new bathroom pass system
NEXT
Boy expelled after disarming classmate’s gun at school
Related Post
October 28, 2025
Family faces potential deportation and separation
November 11, 2025
Nov. 11, 2025, 3:00 PM ESTBy Berkeley Lovelace Jr.As President Donald Trump touts new deals to cut the cost of blockbuster drugs like Wegovy and Zepbound, he’s barely mentioned Medicare’s drug price negotiation program — even though the government is expected to announce lower prices before the end of the month.The program, created under President Joe Biden’s Inflation Reduction Act of 2022, gave Medicare the authority to negotiate directly with drugmakers on some of the costliest medications. A Centers for Medicare and Medicaid Services (CMS) spokesperson said the agency is preparing to release the second round of negotiated prices by Nov. 30 — covering 15 drugs, up from 10 last year, and adding Ozempic and Wegovy to the list. The newly negotiated prices won’t take effect until 2027. Trump announces deal to lower cost of weight loss drug01:59The lack of attention has puzzled health policy experts, who say the program could play an important role in lowering prescription drug costs for millions of older adults in the U.S.About 1-in-5 adults say they’ve not filled a prescription because of cost, according to a poll from the nonpartisan health policy research group KFF.“Certainly, the flurry of announcements and lack of details [on negotiations] make things confusing,” said Dr. Benjamin Rome, a primary care physician and health policy researcher at Harvard Medical School. Trump’s approach to lowering drug prices has leaned heavily on executive orders and voluntary deals with drugmakers, rather than legislation. Last week, he announced agreements with Novo Nordisk and Eli Lilly — the makers of Wegovy and Zepbound, respectively — to lower prices for some doses in exchange for tariff relief and accelerated Food and Drug Administration review of new drugs. Several experts described the details as murky and questioned whether the agreements would translate into real savings for Americans. Trump has struck similar deals with Pfizer and Astrazenca.Rome said the Medicare negotiation program is seen as the steadier, more reliable path to lowering costs for Americans.Drugmakers can decline to participate — but doing so would likely require pulling their drugs from Medicare entirely, cutting them off from one of the nation’s largest markets. Several companies have challenged the negotiation program in court, but those lawsuits have so far been unsuccessful. “Although it’s great that the Trump administration wants to aggressively negotiate lower prices with pharmaceutical companies, these ad hoc negotiations seem to be more about announcing short-term political victories,” Rome said. “I would be very skeptical of relying solely on voluntary deals with drug manufacturers as a main policy for making medications more affordable to Americans,” Rome added. “By contrast, the IRA absolutely will save money for taxpayers through the negotiation process.”Despite the looming announcement, the White House has said little publicly about the negotiation program or how it fits into Trump’s broader push to lower drug prices.In an emailed statement, White House spokesperson Kush Desai said: “Democrats endlessly touted the Inflation Reduction Act, which ironically under Biden’s watch did little but increase Medicare premiums. The Trump administration is focused on results, and our historic drug pricing deals with global pharmaceutical giants are proof that we will continue to deliver meaningful change for the American people.”Last year, the Biden administration announced agreements to lower prices on 10 prescription drugs under Medicare, with those cuts set to take effect in 2026. The drugs included the blockbuster blood thinner Eliquis, along with several cancer and diabetes treatments. At the time, administration officials projected the negotiations would save Medicare enrollees $1.5 billion in out-of-pocket costs in the first year. Experts say the second round may have an even larger impact than last year’s since some of the drugs on the list — particularly Ozempic and Wegovy — are becoming the most widely used and most expensive in Medicare.The Congressional Budget Office, a nonpartisan government group that provides budget and economic information to Congress, projects that, because of negotiations, the net price of Ozempic and Wegovy will “fall substantially” beginning in 2027 — cutting Medicare’s spending on each patient who uses the drugs by one third. The CBO also expects that those lower prices are likely to put pressure on other GLP-1 drugs, including Mounjaro and Zepbound.Stacie Dusetzina, a health policy professor at Vanderbilt University in Nashville, Tennessee, said it’s possible the negotiations may have factored into Trump’s deal on Wegovy and Zepbound last week. When asked on a call with reporters whether Trump’s deal was related to the negotiations, senior administration officials insisted it was not. “We’re all eagerly awaiting the announcement of what prices have been negotiated,” Dusetzina said. “It could very well be that this is where the negotiations landed.”Other experts raised questions about how Trump’s deal fits with the negotiations — or whether the two efforts are even aligned at all. Tricia Neuman, executive director of the program on Medicare policy at KFF, said it’s “not clear how the recent White House announcement dovetails with the Inflation Reduction Act when it comes to negotiated prices for GLP-1s.”Rome said Trump’s deals are unlikely to interfere or undermine the negotiation process.“That process is very clearly spelled out by CMS and has been ongoing throughout the year and will repeat for another 20 drugs early next year,” he said. “I don’t think these side deals with Lilly and Novo will change that.” Neuman added that while the voluntary deals may be drawing more attention from the White House, they don’t replace the long term impacts of Medicare negotiations.“The IRA’s Medicare negotiations program is baked into the law, and is up and running, and could ultimately lead to lower prices for far more drugs over time,” she said. Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
September 26, 2025
Netanyahu checks off countries on Middle East map with enemies Israel has targeted
November 14, 2025
Blue Origin launches New Glenn rocket
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved